Latest news and press releases about Halozyme Therapeutics, Inc. (HALO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Price
| Price | $108.44 |
| Market Cap | $12.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 30.18 |
| Price / Book | 86.81 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 78.18% |
| Operating Margin | 56.77% |
| Net Margin | 24.86% |
Related companies: ABVX · ATR · CAI · CORT · CYTK · GRFS · HSIC
Explore sector: Healthcare · Biotechnology
More sections of HALO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks